- R&D Pipeline
- Season 2 (2021-2030)
| Modality | Indication | Targets | Stage | Company | Project No. | Detail | |
|---|---|---|---|---|---|---|---|
| 1 | IM.101: Complement Inhibitor for Autoimmune Diseases | ||||||
| Antibody | Autoimmune diseases | Human Complement C5 | Phase 1 | ImmunAbs | RS-2023-00258444 | ||
| 2 | Development of a therapeutic agent for ulcerative colitis by regulating glycogen metabolism of immune cells and intestinal epithelial cells | ||||||
| Small Molecules | Ulcerative Colitis | PYGL | Phase 1 | INNOVO Therapeutics | RS-2022-00166802 | ||
| 3 | Topical immunotherapeutic agent for atopic dermatitis : FPR2-selective pro-resolving peptide ligand | ||||||
| Peptide | Atopic dermatitis | FPR2 | Phase 1 | Novacell technology Inc. | HN21C1061 | ||